ENDPOINTS NEWS1h
Sage sues Bio­gen days af­ter $469M buy­out of­fer
Sage Therapeutics has sued Biogen in Delaware court, one week after receiving a $469 million buyout offer from the larger ...
ENDPOINTS NEWS4h
What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions
CMS didn't wait for President-elect Donald Trump to take office before issuing its second list of drugs to be negotiated ...
ENDPOINTS NEWS7h
WuXi AppTec sells med­ical de­vice test­ing unit; Lay­offs at Notch Ther­a­peu­tics
WuXi AppTec sells US device testing sites to NAMSA, Notch Therapeutics cuts staff, and Neurizon's ALS drug NUZ-001 faces FDA clinical hold.
ENDPOINTS NEWS7h
No­vo claims high-dose Phase 3 We­govy win but sales im­pact might be mut­ed
Novo Nordisk's high-dose Wegovy shows 20.7% weight loss in Phase 3 but falls short of Eli Lilly's Zepbound, raising questions ...
ENDPOINTS NEWS9h
Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions
Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare ...
ENDPOINTS NEWS11h
As­traZeneca wins BTK race to mar­ket in first-line man­tle cell lym­phoma
FDA approves AstraZeneca's Calquence as first BTK inhibitor for first-line mantle cell lymphoma, leading BeiGene's Brukinsa ...
ENDPOINTS NEWS11h
Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down
Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze ...
ENDPOINTS NEWS11h
Af­ter three-month de­lay, Am­gen’s Lumakras clinch­es FDA green light in col­orec­tal can­cer
FDA approves Amgen's Lumakras with Vectibix for metastatic colorectal cancer with KRAS G12C mutation, based on Phase 3 ...